Chinese Biotech Files World's First Approval Application for 4-1BB Bispecific Antibody ...

Leads Biolabs, a Chinese biotech, has filed for priority regulatory approval in China for Opartystomig, a bispecific antibody targeting PD-L1 and 4-1BB, potentially becoming the world's first approved 4-1BB-targeting therapy that overcomes big pharma toxicity issues.

This Wire brief sits within Fusion42's coverage of Biotech.